In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Paragraph: We characterized DBD by measuring concentrations of reactive species and ions. The inactivation efficiency was deduced using aerosol-and colony-counting methods. Susceptibility constant (Z) was introduced for performance evaluation of DBD. Modified Z was suggested for evaluation of DBD reactors of different sizes. Our methodology will be used for design optimization and performance evaluation. Dielectric barrier discharge (DBD) is a promising method to remove contaminant bioaerosols. The collection efficiency of a DBD reactor is an important factor for determining a reactor's removal efficiency. Without considering collection, simply defining the inactivation efficiency based on colony counting numbers for DBD as on and off may lead to overestimation of the inactivation efficiency of the DBD reactor. One-pass removal tests of bioaerosols were carried out to deduce the inactivation efficiency of the DBD reactor using both aerosol-and colony-counting methods. Our DBD reactor showed good performance for removing test bioaerosols for an applied voltage of 7.5 kV and a residence time of 0.24 s, with Á CFU , Á Number , and Á Inactivation values of 94%, 64%, and 83%, respectively. Additionally, we introduce the susceptibility constant of bioaerosols to DBD as a quantitative parameter for the performance evaluation of a DBD reactor. The modified susceptibility constant, which is the ratio of the susceptibility constant to the volume of the plasma reactor, has been successfully demonstrated for the performance evaluation of different sized DBD reactors under different DBD operating conditions. Our methodology will be used for design optimization, performance evaluation, and prediction of power consumption of DBD for industrial applications. 
 Title: Susceptibility constants of airborne bacteria to dielectric barrier discharge for antibacterial performance evaluation
False

Paragraph: Background: On the 30th September 2009, the pandemic (H1N1) 2009 influenza vaccine was made available to adults and children aged 10 years and over, in Australia. Acceptance of a novel vaccine is influenced by perceptions of risk including risk of infection, risk of death or severe illness and risk of serious vaccine side-effects. We surveyed a sample of residents from Sydney, Australia to ascertain their risk perception, attitudes towards the pandemic and willingness to accept the pandemic (H1N1) 2009 influenza vaccine. We sampled residents using a cross-sectional intercept design during the WHO Phase 6. Members of the public were approached in shopping and pedestrian malls to undertake the survey during September and October 2009. The survey measured perceived risk, seriousness of disease, recent behavioural changes, likely acceptance of the pandemic (H1N1) 2009 vaccine and issues relating to uptake and perceived safety. 
 Title: Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine
True

Paragraph: | Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies. NATURE REVIEWS | IMMUNOLOGY VOLUME 18 | MAY 2018 | 297 REVIEWS © 2 0 1 8 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d . Genetically engineered mouse antibodies in which the protein sequence has been modified to increase its similarity to human antibodies, thereby decreasing its potential immunogenicity. 
 Title: Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

False